

Nancy Diazgranados

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5944345/publications.pdf>

Version: 2024-02-01

41
papers

5,512
citations

218381

26
h-index

288905

40
g-index

43
all docs

43
docs citations

43
times ranked

6194
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study. <i>Interactive Journal of Medical Research</i> , 2022, 11, e29880.	0.6	16
2	Elevated transferrin saturation in individuals with alcohol use disorder: Association with HFE polymorphism and alcohol withdrawal severity. <i>Addiction Biology</i> , 2022, 27, e13144.	1.4	2
3	Shared genetic risk between eating disorder and substance use related phenotypes: Evidence from genome-wide association studies. <i>Addiction Biology</i> , 2021, 26, e12880.	1.4	28
4	<i>TSPO</i> polymorphism in individuals with alcohol use disorder: Association with cholesterol levels and withdrawal severity. <i>Addiction Biology</i> , 2021, 26, e12838.	1.4	9
5	Ketogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents. <i>Science Advances</i> , 2021, 7, .	4.7	41
6	Common Factors Underlying Diverse Responses in Alcohol Use Disorder. <i>Psychiatric Research and Clinical Practice</i> , 2021, 3, 76-87.	1.3	4
7	Characteristics Associated With High-Intensity Binge Drinking in Alcohol Use Disorder. <i>Frontiers in Psychology</i> , 2021, 12, 750395.	1.1	3
8	A large-scale genome-wide association study meta-analysis of cannabis use disorder. <i>Lancet Psychiatry</i> , 2020, 7, 1032-1045.	3.7	200
9	A Distinct Neurophenotype of Fearful Face Processing in Alcohol Use Disorder With and Without Comorbid Anxiety. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2212-2224.	1.4	1
10	Alcohol effects on globus pallidus connectivity: Role of impulsivity and binge drinking. <i>PLoS ONE</i> , 2020, 15, e0224906.	1.1	15
11	Longitudinal gut microbiome changes in alcohol use disorder are influenced by abstinence and drinking quantity. <i>Gut Microbes</i> , 2020, 11, 1608-1631.	4.3	36
12	History of suicidality and alcohol craving trajectories during inpatient treatment for alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107918.	1.6	5
13	Addiction neurocircuitry and negative affect: A role for neuroticism in understanding amygdala connectivity and alcohol use disorder. <i>Neuroscience Letters</i> , 2020, 722, 134773.	1.0	12
14	PPAR γ activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study. <i>Psychopharmacology</i> , 2020, 237, 2367-2380.	1.5	14
15	Striatal Dopamine Release in Response to Morphine: A [11 C]Raclopride Positron Emission Tomography Study in Healthy Men. <i>Biological Psychiatry</i> , 2019, 86, 356-364.	0.7	20
16	Resting state connectivity best predicts alcohol use severity in moderate to heavy alcohol users. <i>NeuroImage: Clinical</i> , 2019, 22, 101782.	1.4	51
17	S205. "Super Bingers": Traits and Consumption Patterns Associated With High-Intensity Drinking. <i>Biological Psychiatry</i> , 2019, 85, S376-S377.	0.7	1
18	Neurofunctional Domains Derived From Deep Behavioral Phenotyping in Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2019, 176, 744-753.	4.0	91

#	ARTICLE	IF	CITATIONS
19	Insula Sensitivity to Unfairness in Alcohol Use Disorder. <i>Alcohol and Alcoholism</i> , 2018, 53, 201-208.	0.9	2
20	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. <i>Nature Neuroscience</i> , 2018, 21, 1656-1669.	7.1	490
21	Risk Locus Identification Ties Alcohol Withdrawal Symptoms to <i>SORCS2</i> . <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2337-2348.	1.4	14
22	Influence of alcoholism and cholesterol on TSPO binding in brain: PET [11C]PBR28 studies in humans and rodents. <i>Neuropsychopharmacology</i> , 2018, 43, 1832-1839.	2.8	57
23	Neural Correlates of Compulsive Alcohol Seeking in Heavy Drinkers. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 1022-1031.	1.1	45
24	A review of factors associated with greater likelihood of suicide attempts and suicide deaths in bipolar disorder: Part II of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1006-1020.	1.3	87
25	Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 785-802.	1.3	122
26	International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. <i>Bipolar Disorders</i> , 2015, 17, 1-16.	1.1	265
27	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 119-128.	1.1	74
28	Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2013, 73, 1213-1221.	0.7	139
29	Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study. <i>Neuropsychopharmacology</i> , 2012, 37, 1526-1533.	2.8	262
30	A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 551-557.	0.7	187
31	Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial. <i>Biological Psychiatry</i> , 2012, 71, 939-946.	0.7	695
32	Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1155-1159.	2.5	165
33	New Therapeutic Targets for Mood Disorders. <i>Scientific World Journal</i> , The, 2010, 10, 713-726.	0.8	50
34	A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. <i>Archives of General Psychiatry</i> , 2010, 67, 793.	13.8	848
35	Glutamatergic Modulators: The Future of Treating Mood Disorders?. <i>Harvard Review of Psychiatry</i> , 2010, 18, 293-303.	0.9	203
36	Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine. <i>Neuropsychopharmacology</i> , 2010, 35, 1415-1422.	2.8	195

#	ARTICLE	IF	CITATIONS
37	Rapid Resolution of Suicidal Ideation After a Single Infusion of an <i>N</i> -Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1605-1611.	1.1	487
38	Ketamine and the next generation of antidepressants with a rapid onset of action. , 2009, 123, 143-150.		229
39	Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders. <i>Current Pharmaceutical Design</i> , 2009, 15, 1595-1611.	0.9	107
40	Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to an <i>N</i> -Methyl-D-Aspartate Antagonist. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1662-1666.	1.1	131
41	A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. <i>Current Psychiatry Reports</i> , 2008, 10, 510-519.	2.1	46